PMC:7377212 / 22593-23191 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"634","span":{"begin":426,"end":444},"obj":"Disease"},{"id":"635","span":{"begin":547,"end":580},"obj":"Disease"}],"attributes":[{"id":"A634","pred":"tao:has_database_id","subj":"634","obj":"MESH:D003141"},{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"MESH:D003141"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Conflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T226","span":{"begin":426,"end":436},"obj":"Disease"},{"id":"T227","span":{"begin":464,"end":477},"obj":"Disease"},{"id":"T228","span":{"begin":547,"end":557},"obj":"Disease"},{"id":"T229","span":{"begin":567,"end":580},"obj":"Disease"}],"attributes":[{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A227","pred":"mondo_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A228","pred":"mondo_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A229","pred":"mondo_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"}],"text":"Conflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T184","span":{"begin":78,"end":79},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T185","span":{"begin":165,"end":168},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T186","span":{"begin":187,"end":188},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T187","span":{"begin":304,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T188","span":{"begin":397,"end":398},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Conflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T306","span":{"begin":114,"end":124},"obj":"Chemical"},{"id":"T307","span":{"begin":489,"end":494},"obj":"Chemical"},{"id":"T308","span":{"begin":592,"end":597},"obj":"Chemical"}],"attributes":[{"id":"A306","pred":"chebi_id","subj":"T306","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A307","pred":"chebi_id","subj":"T307","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A308","pred":"chebi_id","subj":"T308","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Conflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group."}

{"project":"LitCovid-sentences","denotations":[{"id":"T125","span":{"begin":0,"end":26},"obj":"Sentence"},{"id":"T126","span":{"begin":27,"end":148},"obj":"Sentence"},{"id":"T127","span":{"begin":149,"end":385},"obj":"Sentence"},{"id":"T128","span":{"begin":386,"end":598},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group."}